Molecular Partners (MOLN) Competitors $3.54 -0.02 (-0.67%) Closing price 08/14/2025 03:50 PM EasternExtended Trading$3.54 0.00 (-0.03%) As of 08/14/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MOLN vs. PRME, EOLS, ORGO, TSHA, MRVI, XNCR, TYRA, TBPH, BCYC, and TRMLShould you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Prime Medicine (PRME), Evolus (EOLS), Organogenesis (ORGO), Taysha Gene Therapies (TSHA), Maravai LifeSciences (MRVI), Xencor (XNCR), Tyra Biosciences (TYRA), Theravance Biopharma (TBPH), Bicycle Therapeutics (BCYC), and Tourmaline Bio (TRML). These companies are all part of the "pharmaceutical products" industry. Molecular Partners vs. Its Competitors Prime Medicine Evolus Organogenesis Taysha Gene Therapies Maravai LifeSciences Xencor Tyra Biosciences Theravance Biopharma Bicycle Therapeutics Tourmaline Bio Molecular Partners (NASDAQ:MOLN) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation. Does the media prefer MOLN or PRME? In the previous week, Prime Medicine had 6 more articles in the media than Molecular Partners. MarketBeat recorded 7 mentions for Prime Medicine and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.87 beat Prime Medicine's score of 0.09 indicating that Molecular Partners is being referred to more favorably in the media. Company Overall Sentiment Molecular Partners Very Positive Prime Medicine Neutral Do analysts rate MOLN or PRME? Molecular Partners currently has a consensus target price of $12.00, indicating a potential upside of 239.37%. Prime Medicine has a consensus target price of $8.92, indicating a potential upside of 144.96%. Given Molecular Partners' stronger consensus rating and higher possible upside, analysts plainly believe Molecular Partners is more favorable than Prime Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Molecular Partners 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Is MOLN or PRME more profitable? Molecular Partners' return on equity of -42.20% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Molecular PartnersN/A -42.20% -38.12% Prime Medicine N/A -107.87%-74.97% Which has more risk & volatility, MOLN or PRME? Molecular Partners has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.39, suggesting that its stock price is 139% more volatile than the S&P 500. Which has higher earnings & valuation, MOLN or PRME? Molecular Partners has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMolecular Partners$5.65M25.27-$61.39M-$1.92-1.84Prime Medicine$4.96M98.74-$198.13M-$1.56-2.33 Do insiders & institutionals believe in MOLN or PRME? 26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 22.7% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryPrime Medicine beats Molecular Partners on 8 of the 15 factors compared between the two stocks. Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOLN vs. The Competition Export to ExcelMetricMolecular PartnersMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$143.63M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-1.8420.4930.2925.74Price / Sales25.27356.37463.41115.79Price / CashN/A43.0338.2159.48Price / Book0.898.608.826.15Net Income-$61.39M-$54.65M$3.25B$265.06M7 Day Performance-0.70%5.86%3.70%2.60%1 Month Performance-0.48%8.86%5.84%2.83%1 Year Performance-44.11%13.33%29.92%25.58% Molecular Partners Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MOLNMolecular Partners2.4371 of 5 stars$3.54-0.7%$12.00+239.4%-43.0%$143.63M$5.65M-1.84180Positive NewsGap DownHigh Trading VolumePRMEPrime Medicine3.6896 of 5 stars$4.37-2.9%$9.25+111.7%-11.4%$587.75M$3.85M-2.13234Analyst RevisionGap DownEOLSEvolus3.8905 of 5 stars$8.91-2.2%$23.75+166.6%-53.4%$587.37M$266.27M0.00170High Trading VolumeORGOOrganogenesis4.22 of 5 stars$4.53-1.5%$6.50+43.5%+82.2%$583.53M$482.04M0.00950TSHATaysha Gene Therapies3.5109 of 5 stars$2.74+1.1%$8.17+198.1%+27.3%$581.73M$8.33M0.00180Earnings ReportAnalyst ForecastMRVIMaravai LifeSciences3.705 of 5 stars$2.34+3.1%$6.64+183.7%-68.4%$578.08M$259.18M0.00610Analyst ForecastXNCRXencor3.6004 of 5 stars$7.95flat$28.00+252.2%-51.4%$565.81M$110.49M-2.60280Gap DownTYRATyra Biosciences2.4407 of 5 stars$11.45+7.5%$30.83+169.3%-50.4%$565.41MN/A0.0020News CoveragePositive NewsEarnings ReportUpcoming EarningsTBPHTheravance Biopharma2.1099 of 5 stars$11.09-1.2%$16.60+49.7%+58.2%$561.02M$64.38M0.00110News CoverageBCYCBicycle Therapeutics3.4704 of 5 stars$7.86-2.4%$24.22+208.2%-66.7%$557.49M$35.28M0.00240Trending NewsEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionTRMLTourmaline Bio2.4002 of 5 stars$22.42+3.8%$49.33+120.0%+65.7%$554.55MN/A0.0044News CoverageEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies Prime Medicine Competitors Evolus Competitors Organogenesis Competitors Taysha Gene Therapies Competitors Maravai LifeSciences Competitors Xencor Competitors Tyra Biosciences Competitors Theravance Biopharma Competitors Bicycle Therapeutics Competitors Tourmaline Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOLN) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access